Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases - 18/04/17
, Francesca Galli, StatSci b, Laura Cattaneo, MD c, Barbara Merelli, MD a, Eliana Rulli, StatSci b, Simone Ribero, MD d, Pietro Quaglino, MD d, Vincenzo De Giorgi, MD e, Jacopo Pigozzo, MD f, Vanna Chiarion Sileni, MD f, Alessandra Chirco, MD a, Pier Francesco Ferrucci, MD g, Marcella Occelli, MD h, Gianlorenzo Imberti, MD i, Dario Piazzalunga, MD j, Daniela Massi, MD k, Carlo Tondini, MD a, Paola Queirolo, MD lon behalf of
Italian Melanoma Intergroup
Abstract |
Background |
The 7th edition of the TNM American Joint Committee on Cancer classification incorporates mitotic rate (MR) only for primary cutaneous melanoma (PCM) with Breslow thickness (BT) ≤1 mm.
Objective |
To investigate whether and to what extent MR is able to predict sentinel lymph node (SLN) status and clinical outcome of PCM patients with BT >1 mm.
Methods |
The study included consecutive patients with PCM. Logistic regression and Cox regression model were used to analyze the impact of MR on SLN status, disease-free survival (DFS), and overall survival.
Results |
From 1998 to 2015, 1524 PCM (median age 57.8 years) cases were diagnosed with a BT >1 mm in six centers of the Italian Melanoma Intergroup. Median follow-up was 5.0 years. By multivariate analysis, MR was associated with SLN positivity (odds ratio 1.98, 95% confidence interval [CI] 1.12-3.50, P = .018). After adjusting for BT, ulceration, age, sex, and SLN status, MR correlated with a poor DFS (hazard ratio 1.52, 95% CI 1.18-1.97, P = .002) and overall survival (hazard ratio 1.63, 95% CI 1.17-2.29, P = .004).
Limitations |
Retrospective analysis.
Conclusion |
MR is an independent prognostic factor for PCM patients with BT >1 mm. Incorporating this tissue biomarker could provide a better stratification of patients entering clinical trials in the adjuvant setting.
Le texte complet de cet article est disponible en PDF.Key words : mitotic rate, cutaneous melanoma, prognosis, disease-free survival, overall survival, sentinel lymph node, outcome
Abbreviations used : AJCC, BT, CI, DFS, HR, IMI, IQR, MR, OR, OS, PCM, SLN, TILs
Plan
| Drs Tondini and Queirolo equally contributed senior authorship. |
|
| Reprints not available from the authors. |
|
| Supplemental items available at www.jaad.org/. |
|
| Supported by Italian Melanoma Intergroup (IMI, grant 3/2015), the Italian network for melanoma treatment and research (www.melanomaimi.it/), grant number IMI 18NOV2014-17NOV2015. |
|
| Conflict of interest: None. |
Vol 76 - N° 2
P. 264 - février 2017 Retour au numéro
Article précédent
- Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013
- Shoshana M. Landow, Annie Gjelsvik, Martin A. Weinstock
- Autoimmune diseases in adults with atopic dermatitis
- Yuki M.F. Andersen, Alexander Egeberg, Gunnar H. Gislason, Lone Skov, Jacob P. Thyssen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?